AstraZeneca PLC(AZN)Earnings, Financials & Key Ratios
AZN•NASDAQ
$181.24
$280.97B mkt cap·27.7× P/E·Price updated May 6, 2026
AboutAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.Show more
- Revenue$58.74B+8.6%
- EBITDA$19.48B+29.3%
- Net Income$10.26B+45.8%
- EPS (Diluted)6.54+190.7%
- Gross Margin81.9%+1.0%
- EBITDA Margin33.16%+19.0%
- Operating Margin23.4%+26.5%
- Net Margin17.46%+34.2%
- ROE22.89%+30.2%
- ROIC14.92%+26.7%
- Debt/Equity0.61-17.3%
- Interest Coverage8.32+34.9%
AZN Key Insights
AstraZeneca PLC (AZN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 26.3%
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 20.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 17.2%
- ✓Good 3Y average ROE of 18.7%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AZN Price & Volume
AstraZeneca PLC (AZN) stock price & volume — 10-year historical chart
Loading chart...
AZN Growth Metrics
AstraZeneca PLC (AZN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.05%
5 Years17.15%
3 Years9.82%
TTM9.93%
Profit CAGR
10 Years13.76%
5 Years26.26%
3 Years46.11%
TTM33.67%
EPS CAGR
10 Years11.36%
5 Years21.8%
3 Years45.8%
TTM33.07%
Return on Capital
10 Years9.3%
5 Years9.81%
3 Years14.16%
Last Year17.22%
AZN Recent Earnings
AstraZeneca PLC (AZN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 29, 2026EPS
$2.58
Est $2.52
+2.4%
Revenue
$15.3B
Est $14.9B
+2.4%
Q1 2026
Feb 10, 2026EPS
$2.12
Est $2.18
-2.8%
Revenue
$15.5B
Est $15.4B
+0.4%
Q4 2025
Nov 6, 2025EPS
$2.38
Est $2.29
+3.9%
Revenue
$15.2B
Est $15.4B
-1.5%
Q3 2025
Jul 29, 2025EPS
$2.18
Est $2.16
+0.9%
Revenue
$14.5B
Est $14.8B
-2.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $2.58vs $2.52+2.4% | $15.3Bvs $14.9B+2.4% |
| Q1 2026 | Feb 10, 2026 | $2.12vs $2.18-2.8% | $15.5Bvs $15.4B+0.4% |
| Q4 2025 | Nov 6, 2025 | $2.38vs $2.29+3.9% | $15.2Bvs $15.4B-1.5% |
| Q3 2025 | Jul 29, 2025 | $2.18vs $2.16+0.9% | $14.5Bvs $14.8B-2.1% |
Based on last 12 quarters of dataView full earnings history →
AZN Peer Comparison
AstraZeneca PLC (AZN) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 NVS | 277.63B | 145.50 | 20.24 | 5.97% | 24.14% | 31.42% | 6.37% | 0.80 |
 SNY | 104.72B | 43.36 | 18.20 | 5.49% | 16.72% | 10.78% | 9.97% | 0.30 |
 GILD | 166.32B | 133.48 | 351.26 | 6.04% | 28.9% | 37.62% | 6.2% | 1.39 |
Compare AZN vs Peers
AstraZeneca PLC (AZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AZN Income Statement
AstraZeneca PLC (AZN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 22.46B | 22.09B | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | 54.07B | 58.74B | 60.44B |
| Revenue Growth % | -2.33% | -1.67% | 10.38% | 9.16% | 40.58% | 18.53% | 3.29% | 18.04% | 8.63% | 9.93% |
| Cost of Goods Sold | 4.32B | 4.94B | 4.92B | 5.3B | 12.44B | 12.39B | 8.27B | 10.21B | 10.63B | 11.07B |
| COGS % of Revenue | 19.22% | 22.35% | 20.18% | 19.91% | 33.24% | 27.94% | 18.05% | 18.88% | 18.1% | - |
| Gross Profit | 18.15B▲ 0% | 17.15B▼ 5.5% | 19.46B▲ 13.5% | 21.32B▲ 9.5% | 24.98B▲ 17.2% | 31.96B▲ 27.9% | 37.54B▲ 17.5% | 43.87B▲ 16.8% | 48.11B▲ 9.7% | 49.37B▲ 0% |
| Gross Margin % | 80.78% | 77.66% | 79.82% | 80.09% | 66.76% | 72.06% | 81.95% | 81.12% | 81.9% | 81.68% |
| Gross Profit Growth % | -3.86% | -5.47% | 13.46% | 9.53% | 17.18% | 27.94% | 17.47% | 16.84% | 9.67% | - |
| Operating Expenses | 14.47B | 13.77B | 16.54B | 16.16B | 23.92B | 28.2B | 29.35B | 33.86B | 34.36B | 35.05B |
| OpEx % of Revenue | 64.41% | 62.32% | 67.83% | 60.7% | 63.94% | 63.59% | 64.07% | 62.62% | 58.5% | - |
| Selling, General & Admin | 10.54B | 10.98B | 11.98B | 11.9B | 15.59B | 17.98B | 18.22B | 20.22B | 20.51B | 20.95B |
| SG&A % of Revenue | 46.93% | 49.71% | 49.15% | 44.69% | 41.67% | 40.55% | 39.78% | 37.4% | 34.92% | - |
| Research & Development | 5.76B | 5.93B | 6.06B | 5.99B | 9.74B | 9.76B | 10.94B | 13.58B | 14.23B | 14.56B |
| R&D % of Revenue | 25.63% | 26.85% | 24.85% | 22.51% | 26.02% | 22.01% | 23.87% | 25.12% | 24.23% | - |
| Other Operating Expenses | -1.83B | -3.15B | -1.5B | -1.73B | -1.4B | 457M | 193M | 56M | -381M | -4M |
| Operating Income | 3.68B▲ 0% | 3.39B▼ 7.9% | 2.92B▼ 13.7% | 5.16B▲ 76.5% | 1.06B▼ 79.5% | 3.76B▲ 255.8% | 8.19B▲ 118.1% | 10B▲ 22.1% | 13.74B▲ 37.4% | 14.31B▲ 0% |
| Operating Margin % | 16.37% | 15.33% | 11.99% | 19.39% | 2.82% | 8.47% | 17.88% | 18.5% | 23.4% | 23.69% |
| Operating Income Growth % | -24.99% | -7.89% | -13.67% | 76.54% | -79.54% | 255.78% | 118.07% | 22.09% | 37.39% | - |
| EBITDA | 6.71B | 7.14B | 6.69B | 8.06B | 5.16B | 9.01B | 13.13B | 15.07B | 19.48B | 20.13B |
| EBITDA Margin % | 29.88% | 32.32% | 27.42% | 30.27% | 13.79% | 20.32% | 28.65% | 27.87% | 33.16% | 33.31% |
| EBITDA Growth % | -7.52% | 6.36% | -6.36% | 20.52% | -35.99% | 74.7% | 45.68% | 14.79% | 29.25% | 28.58% |
| D&A (Non-Cash Add-back) | 3.04B | 3.75B | 3.76B | 2.9B | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B | 5.82B |
| EBIT | 3.59B | 3.36B | 2.95B | 5.19B | 1.01B | 3.83B | 8.49B | 10.37B | 14.1B | 14.65B |
| Net Interest Income | -1.25B | -1.23B | -1.24B | -1.19B | -1.23B | -1.25B | -1.29B | -1.34B | -1.33B | -1.39B |
| Interest Income | 109M | 138M | 165M | 83M | 43M | 81M | 301M | 345M | 360M | 349M |
| Interest Expense | 1.36B | 1.37B | 1.4B | 1.27B | 1.28B | 1.33B | 1.59B | 1.68B | 1.69B | 1.74B |
| Other Income/Expense | -1.45B | -1.39B | -1.38B | -1.25B | -1.32B | -1.26B | -1.29B | -1.31B | -1.34B | -1.4B |
| Pretax Income | 2.23B▲ 0% | 1.99B▼ 10.5% | 1.55B▼ 22.3% | 3.92B▲ 153.0% | -265M▼ 106.8% | 2.5B▲ 1043.8% | 6.9B▲ 175.8% | 8.69B▲ 26.0% | 12.4B▲ 42.7% | 12.91B▲ 0% |
| Pretax Margin % | 9.91% | 9.02% | 6.35% | 14.71% | -0.71% | 5.64% | 15.06% | 16.07% | 21.11% | 21.37% |
| Income Tax | -641M | -57M | 321M | 772M | -380M | -792M | 938M | 1.65B | 2.17B | 2.52B |
| Effective Tax Rate % | -28.78% | -2.86% | 20.74% | 19.71% | 143.4% | -31.67% | 13.6% | 18.99% | 17.49% | 19.52% |
| Net Income | 3B▲ 0% | 2.15B▼ 28.2% | 1.33B▼ 38.1% | 3.2B▲ 139.4% | 112M▼ 96.5% | 3.29B▲ 2835.7% | 5.96B▲ 81.1% | 7.04B▲ 18.1% | 10.26B▲ 45.8% | 10.39B▲ 0% |
| Net Margin % | 13.36% | 9.76% | 5.47% | 12.01% | 0.3% | 7.41% | 13% | 13.01% | 17.46% | 17.19% |
| Net Income Growth % | -14.23% | -28.19% | -38.05% | 139.4% | -96.5% | 2835.71% | 81.11% | 18.14% | 45.77% | 33.67% |
| Net Income (Continuing) | 2.87B | 2.05B | 1.23B | 3.14B | 115M | 3.29B | 5.96B | 7.04B | 10.23B | 10.39B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.68B | 1.58B | 1.47B | 16M | 19M | 21M | 23M | 85M | 52M | 51M |
| EPS (Diluted) | 2.37▲ 0% | 1.70▼ 28.3% | 1.03▼ 39.4% | 2.44▲ 136.9% | 0.08▼ 96.7% | 2.11▲ 2537.5% | 3.81▲ 80.6% | 2.25▼ 40.9% | 6.54▲ 190.7% | 6.66▲ 0% |
| EPS Growth % | -14.13% | -28.27% | -39.41% | 136.89% | -96.72% | 2537.5% | 80.57% | -40.94% | 190.67% | 33.07% |
| EPS (Basic) | 2.37 | 1.70 | 1.03 | 2.44 | 0.08 | 2.12 | 3.81 | 2.27 | 6.60 | - |
| Diluted Shares Outstanding | 1.27B | 1.27B | 1.3B | 1.31B | 1.43B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Basic Shares Outstanding | 1.27B | 1.27B | 1.3B | 1.31B | 1.42B | 1.55B | 1.56B | 1.55B | 1.55B | 1.55B |
| Dividend Payout Ratio | 117.26% | 161.67% | 269.06% | 111.76% | 3442.86% | 132.73% | 75.25% | 65.8% | 49.55% | - |
AZN Balance Sheet
AstraZeneca PLC (AZN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 13.15B | 15.59B | 15.56B | 19.54B | 26.24B | 22.59B | 25.05B | 25.83B | 28.72B | 29.61B |
| Cash & Short-Term Investments | 4.55B | 5.68B | 6.22B | 7.99B | 6.4B | 6.24B | 5.86B | 5.53B | 5.74B | 7.67B |
| Cash Only | 3.32B | 4.83B | 5.37B | 7.83B | 6.33B | 6.17B | 5.84B | 5.49B | 5.71B | 7.56B |
| Short-Term Investments | 1.23B | 849M | 849M | 160M | 69M | 77M | 20M | 37M | 30M | 115M |
| Accounts Receivable | 2.8B | 3B | 4.9B | 5.65B | 8.13B | 9.19B | 8.41B | 11.23B | 15.18B | 14.11B |
| Days Sales Outstanding | 45.53 | 49.49 | 73.29 | 77.49 | 79.33 | 75.65 | 66.98 | 75.84 | 94.31 | 87.25 |
| Inventory | 3.04B | 2.89B | 3.19B | 4.02B | 8.98B | 4.7B | 5.42B | 5.29B | 6.56B | 6.57B |
| Days Inventory Outstanding | 256.55 | 213.71 | 236.83 | 277.18 | 263.63 | 138.42 | 239.45 | 189.1 | 225.08 | 215.86 |
| Other Current Assets | 1.68B | 3.08B | 392M | 142M | 1.22B | 1.13B | 3.75B | 2.04B | 1.25B | 1.26B |
| Total Non-Current Assets | 50.2B | 45.06B | 45.81B | 47.19B | 79.12B | 73.89B | 76.06B | 78.21B | 85.35B | 84.4B |
| Property, Plant & Equipment | 7.62B | 7.42B | 8.34B | 8.92B | 10.17B | 9.45B | 10.5B | 11.65B | 14.7B | 14.94B |
| Fixed Asset Turnover | 2.95x | 2.98x | 2.93x | 2.98x | 3.68x | 4.69x | 4.36x | 4.64x | 4.00x | 4.27x |
| Goodwill | 11.82B | 11.71B | 11.67B | 11.85B | 20B | 19.82B | 20.05B | 21.02B | 21.24B | 21.19B |
| Intangible Assets | 26.19B | 21.96B | 20.83B | 20.95B | 42.39B | 39.31B | 38.09B | 37.18B | 37.85B | 36.91B |
| Long-Term Investments | -194M | 113M | 0 | 0 | 0 | 0 | 1.78B | 0 | 2.52B | 13.91B |
| Other Non-Current Assets | 2.58B | 1.48B | 2.26B | 2.04B | 2.23B | 2.05B | 5.65B | 3.01B | 9.04B | 13.77B |
| Total Assets | 63.35B▲ 0% | 60.65B▼ 4.3% | 61.38B▲ 1.2% | 66.73B▲ 8.7% | 105.36B▲ 57.9% | 96.48B▼ 8.4% | 101.12B▲ 4.8% | 104.03B▲ 2.9% | 114.07B▲ 9.6% | 114.02B▲ 0% |
| Asset Turnover | 0.35x | 0.36x | 0.40x | 0.40x | 0.36x | 0.46x | 0.45x | 0.52x | 0.51x | 0.53x |
| Asset Growth % | 1.32% | -4.27% | 1.2% | 8.72% | 57.9% | -8.43% | 4.81% | 2.88% | 9.65% | 33.79% |
| Total Current Liabilities | 16.38B | 16.29B | 18.12B | 20.31B | 22.59B | 26.29B | 30.54B | 27.87B | 30.62B | 32.57B |
| Accounts Payable | 2.29B | 1.72B | 1.77B | 2.35B | 2.82B | 2.55B | 3.27B | 3.64B | 25.28B | 22.5B |
| Days Payables Outstanding | 193.15 | 127.19 | 131.58 | 161.87 | 82.88 | 75.11 | 144.23 | 130.17 | 867.79 | 797.91 |
| Short-Term Debt | 2.27B | 1.78B | 1.82B | 2.19B | 1.57B | 5.22B | 5.13B | 2.16B | 3.19B | 7.58B |
| Deferred Revenue (Current) | -6.44B | 1.37B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.21B | 3.73B | 9.96B | 12.27B | 14.94B | 15B | 6.13B | 17.31B | 686M | 807M |
| Current Ratio | 0.80x | 0.96x | 0.86x | 0.96x | 1.16x | 0.86x | 0.82x | 0.93x | 0.94x | 0.94x |
| Quick Ratio | 0.62x | 0.78x | 0.68x | 0.76x | 0.76x | 0.68x | 0.64x | 0.74x | 0.72x | 0.72x |
| Cash Conversion Cycle | 108.92 | 136 | 178.54 | 192.8 | 260.08 | 138.95 | 162.21 | 134.77 | -548.4 | -494.81 |
| Total Non-Current Liabilities | 30.33B | 30.32B | 28.66B | 30.78B | 43.48B | 33.13B | 31.41B | 35.3B | 34.74B | 34.06B |
| Long-Term Debt | 17.39B | 19.2B | 15.73B | 17.5B | 28.13B | 22.96B | 22.36B | 26.51B | 24.71B | 24.45B |
| Capital Lease Obligations | 0 | 0 | 487M | 489M | 754M | 725M | 857M | 1.11B | 1.42B | 5.58B |
| Deferred Tax Liabilities | 4B | 3.29B | 2.49B | 2.92B | 6.21B | 2.94B | 31M | 3.31B | 3.51B | 14.19B |
| Other Non-Current Liabilities | 12.94B | 11.11B | 9.91B | 9.83B | 8.36B | 6.48B | 8.15B | 4.37B | 5.1B | 18.96B |
| Total Liabilities | 46.71B | 46.61B | 46.78B | 51.09B | 66.08B | 59.42B | 61.95B | 63.16B | 65.36B | 66.63B |
| Total Debt | 17.81B | 19.11B | 18.23B | 20.38B | 30.69B | 29.14B | 28.62B | 30.11B | 29.7B | 33.92B |
| Net Debt | 14.48B | 14.28B | 12.86B | 12.55B | 24.36B | 22.98B | 22.78B | 24.63B | 23.99B | 26.36B |
| Debt / Equity | 1.07x | 1.36x | 1.25x | 1.30x | 0.78x | 0.79x | 0.73x | 0.74x | 0.61x | 0.61x |
| Debt / EBITDA | 2.65x | 2.68x | 2.73x | 2.53x | 5.95x | 3.23x | 2.18x | 2.00x | 1.53x | 1.68x |
| Net Debt / EBITDA | 2.16x | 2.00x | 1.92x | 1.56x | 4.72x | 2.55x | 1.74x | 1.63x | 1.23x | 1.23x |
| Interest Coverage | 2.64x | 2.46x | 2.10x | 4.08x | 0.79x | 2.88x | 5.34x | 6.17x | 8.32x | 8.43x |
| Total Equity | 16.64B▲ 0% | 14.04B▼ 15.6% | 14.6B▲ 3.9% | 15.64B▲ 7.1% | 39.29B▲ 151.2% | 37.06B▼ 5.7% | 39.17B▲ 5.7% | 40.87B▲ 4.4% | 48.72B▲ 19.2% | 47.38B▲ 0% |
| Equity Growth % | -0.16% | -15.61% | 3.93% | 7.14% | 151.23% | -5.67% | 5.69% | 4.35% | 19.2% | 60.23% |
| Book Value per Share | 13.13 | 11.08 | 11.22 | 11.91 | 27.53 | 23.76 | 25.07 | 26.15 | 31.19 | 30.35 |
| Total Shareholders' Equity | 14.96B | 12.47B | 13.13B | 15.62B | 39.27B | 37.04B | 39.14B | 40.79B | 48.67B | 47.33B |
| Common Stock | 317M | 317M | 328M | 328M | 387M | 387M | 388M | 388M | 388M | 388M |
| Retained Earnings | 8.22B | 5.68B | 2.81B | 5.3B | 1.71B | -574M | 4.52B | 3.16B | 10.97B | 9.67B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.01B | 34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.68B | 1.58B | 1.47B | 16M | 19M | 21M | 23M | 85M | 52M | 51M |
AZN Cash Flow Statement
AstraZeneca PLC (AZN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.58B | 2.62B | 2.97B | 4.8B | 5.96B | 9.81B | 10.35B | 11.86B | 14.57B | 14.57B |
| Operating CF Margin % | 15.93% | 11.85% | 12.18% | 18.03% | 15.94% | 22.11% | 22.58% | 21.94% | 24.81% | - |
| Operating CF Growth % | -13.68% | -26.83% | 13.41% | 61.64% | 24.26% | 64.48% | 5.48% | 14.65% | 22.88% | 35.57% |
| Net Income | 2.23B | 1.99B | 1.55B | 3.92B | -265M | 2.5B | 6.9B | 8.69B | 10.22B | 10.39B |
| Depreciation & Amortization | 3.04B | 3.75B | 3.76B | 3.15B | 6.53B | 5.48B | 4.93B | 5.07B | 5.73B | 5.83B |
| Stock-Based Compensation | 0 | 0 | 259M | 277M | 615M | 619M | 579M | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | -259M | -277M | -615M | -619M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.64B | -2.49B | -2B | -2.63B | -2.32B | -1.93B | -2.37B | -1B | -220.71M | -1.72B |
| Working Capital Changes | -50M | -639M | -346M | 361M | 2.02B | 3.76B | 300M | -893M | -1.16B | -1.74B |
| Change in Receivables | 83M | -523M | -898M | -739M | -961M | -1.35B | -1.43B | -1.62B | 0 | 0 |
| Change in Inventory | -548M | -13M | -316M | -621M | 1.58B | 3.94B | -669M | -131M | 0 | 0 |
| Change in Payables | 0 | 0 | 898M | 739M | 961M | 1.35B | 1.43B | 0 | 0 | 0 |
| Cash from Investing | -2.33B | 963M | -657M | -285M | -11.06B | -2.96B | -4.06B | -7.98B | -6.81B | -7.42B |
| Capital Expenditures | -1.62B | -1.37B | -2.46B | -2.61B | -2.2B | -2.57B | -1.36B | -1.92B | -2.81B | -3.19B |
| CapEx % of Revenue | 7.21% | 6.21% | 10.09% | 9.79% | 5.88% | 5.8% | 2.97% | 3.56% | 4.78% | - |
| Acquisitions | -1.96B | -536M | -783M | -830M | -9.43B | -1.06B | -1.18B | -3.93B | -1.23B | -1.13B |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.62B | 2.54B | 2.39B | 1.14B | 654M | 789M | -1.52B | -2.14B | -2.77B | -2.93B |
| Cash from Financing | -2.94B | -2.04B | -1.76B | -2.2B | 3.65B | -6.82B | -6.57B | -4B | -7.54B | -4.65B |
| Debt Issued (Net) | 224M | 1.47B | -1.19B | 1.65B | 7.89B | -1.2B | -965M | 1.81B | -1.69B | 1.38B |
| Equity Issued (Net) | 43M | 34M | 3.52B | 30M | 29M | 29M | 33M | -43M | -678.77M | -784.17M |
| Dividends Paid | -3.52B | -3.48B | -3.59B | -3.57B | -3.86B | -4.36B | -4.48B | -4.63B | -5.08B | -4.89B |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -719.66M | -211.58M |
| Other Financing | 316M | -67M | -512M | -308M | -418M | -1.29B | -1.15B | -1.13B | -133.68M | -358.46M |
| Net Change in Cash | -1.75B▲ 0% | 1.5B▲ 185.6% | 552M▼ 63.2% | 2.32B▲ 320.8% | -1.51B▼ 164.9% | -55M▲ 96.4% | -346M▼ 529.1% | -208M▲ 39.9% | 269M▲ 229.3% | 2.28B▲ 0% |
| Free Cash Flow | 1.96B▲ 0% | 1.25B▼ 36.3% | 509M▼ 59.2% | 2.19B▲ 330.8% | 3.76B▲ 71.6% | 7.24B▲ 92.3% | 6.57B▼ 9.3% | 7.28B▲ 10.8% | 11.77B▲ 61.7% | 9.11B▲ 0% |
| FCF Margin % | 8.72% | 5.65% | 2.09% | 8.24% | 10.06% | 16.32% | 14.34% | 13.45% | 20.03% | 15.07% |
| FCF Growth % | 6.94% | -36.31% | -59.18% | 330.84% | 71.59% | 92.32% | -9.26% | 10.78% | 61.72% | -5.88% |
| FCF per Share | 1.55 | 0.98 | 0.39 | 1.67 | 2.64 | 4.64 | 4.20 | 4.65 | 7.53 | 7.53 |
| FCF Conversion (FCF/Net Income) | 1.19x | 1.21x | 2.22x | 1.50x | 53.24x | 2.98x | 1.74x | 1.69x | 1.42x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 446M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AZN Key Ratios
AstraZeneca PLC (AZN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 18.02% | 14.05% | 9.32% | 21.14% | 0.41% | 8.61% | 15.63% | 17.58% | 22.89% | 22.24% |
| Return on Invested Capital (ROIC) | 9.26% | 8.55% | 7.86% | 13.92% | 1.72% | 4.56% | 10.07% | 11.77% | 14.92% | 14.92% |
| Gross Margin | 80.78% | 77.66% | 79.82% | 80.09% | 66.76% | 72.06% | 81.95% | 81.12% | 81.9% | 81.68% |
| Net Margin | 13.36% | 9.76% | 5.47% | 12.01% | 0.3% | 7.41% | 13% | 13.01% | 17.46% | 17.19% |
| Debt / Equity | 1.07x | 1.36x | 1.25x | 1.30x | 0.78x | 0.79x | 0.73x | 0.74x | 0.61x | 0.61x |
| Interest Coverage | 2.64x | 2.46x | 2.10x | 4.08x | 0.79x | 2.88x | 5.34x | 6.17x | 8.32x | 8.43x |
| FCF Conversion | 1.19x | 1.21x | 2.22x | 1.50x | 53.24x | 2.98x | 1.74x | 1.69x | 1.42x | 0.88x |
| Revenue Growth | -2.33% | -1.67% | 10.38% | 9.16% | 40.58% | 18.53% | 3.29% | 18.04% | 8.63% | 9.93% |
AZN Frequently Asked Questions
AstraZeneca PLC (AZN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AstraZeneca PLC (AZN) reported $60.44B in revenue for fiscal year 2025. This represents a 558% increase from $9.18B in 1996.
AstraZeneca PLC (AZN) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AstraZeneca PLC (AZN) is profitable, generating $10.39B in net income for fiscal year 2025 (17.5% net margin).
Dividend & Returns
Yes, AstraZeneca PLC (AZN) pays a dividend with a yield of 1.80%. This makes it attractive for income-focused investors.
AstraZeneca PLC (AZN) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.
AstraZeneca PLC (AZN) generated $9.11B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More AZN
AstraZeneca PLC (AZN) financial analysis — history, returns, DCA and operating performance tools
Full AZN Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates